European Primary Care Cardiovascular Society

Diabetes

Diabetes is now considered an important risk factor for cardiovascular disease, and a complex interplay of pathogenic factors complicates management of both diseases.

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 11, 2023 - Amy Groenewegen, MD

Elevated inflammation markers in diabetes: a cause or a consequence?

3' education - June 26, 2023 - Peter Libby, MD

Evaluating the role of a non-steroidal MRA in patients with T2DM and CKD

10' education - Feb. 8, 2022 - Prof. Peter Rossing, MD, prof. Gerasimos Filippatos, MD and prof. Matthew Weir, MD

Does low-dose aspirin lower risk of dementia in T2DM?

3' education - Nov. 16, 2021 - Prof. Jane Armitage

CV and renal benefit predicted by reduction in albuminuria in T2DM

10' education - Apr. 15, 2021 - Frederik Persson, MD

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD

CVD prevention with GLP-1 receptor agonists

10' education - Nov. 10, 2020 - Prof. Kamlesh Khunti, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD

Reliable results with NOAC plus aspirin in CAD and PAD with and without diabetes

3' education - Apr. 9, 2020 - Prof. Deepak Bhatt, MD

Better insight into current daily clinical practice and more collaboration is needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu

Why we need updated Diabetes Guidelines and new recommendations

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

Policy recommendations to stimulate implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Cornelia Bala - European Diabetes Policy Summit

Implementation of guidelines: identifying barriers

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
EPCCS Annual CV Summit

Update on managing CV risk in diabetes: what's the evidence?

5' education - Mar. 22, 2019 - Lisbon, Portugal - Kamlesh Khunti & Richard Hobbs

EPCCS

3' education - Feb. 8, 2019

The cardiovascular challenge for primary care in diabetes

10' education - July 10, 2018 - Prof. Richard Hobbs - Oxford, UK

Consideration of SGLT2 inhibitor treatment in broader T2DM population

3' education - Nov. 26, 2018 - Steve Wiviott, MD - Boston, MA, VS.

CV safety with weight loss agent in high-risk overweight or obese patients

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No overall benefit with aspirin in a primary prevention setting of diabetes patients

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Omega-3 fatty acid supplements do not result in CV benefits

3' education - Aug. 26, 2018 - Dr Louise Bowman, Oxford, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - July 17, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (2/3)

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - July 12, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Management of CV risk that comes with T2DM in light of novel treatment options

10' education - Mar. 15, 2018 - EPCCS 2018, Barcelona, Spain - Dr. Carlos Brotons, prof. Xavier Cos, prof. Richard Hobbs

Striking results for weight reduction in T2DM in primary care based program

3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK

The evidence base for health behaviour changes

10' education - Dec. 9, 2015 - EPCCS 2015 - Prague, Czech Republic

What's the evidence for BP and lipid targets in diabetes?

3' education - Nov. 25, 2014 - EPCCS 2014, Brussels

High and increasing prevalence of cardio-renal-metabolic multimorbidity

Literature - Oct. 23, 2023 - Ostrominski JW, et al. - JAMA Cardiol. 2023

A population-based cohort study showed that cardio-renal-metabolic conditions (CVD, CKD, and T2D) and their overlap were increasingly common among US adults over the last 2 decades.

Effects of GLP-1RA on top of SGLT2 inhibitor on albuminuria in patients with T2D and albuminuria

News - Oct. 11, 2023

EASD 2023 A small randomized study showed that treatment with GLP-1RA semaglutide on top of empagliflozin did not have an additional beneficial effect on albuminuria in patients with T2D and albuminuria compared with placebo.

New diagnostic strategy to improve early CVD diagnosis in primary care patients with COPD or T2D

3' education - Oct. 11, 2023 - Amy Groenewegen, MD
**ESC Congress 2023** In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

ESC Congress 2023 In the RED-CVD study, it was investigated whether a new diagnostic strategy could increase the number of new CVD diagnoses in primary care patients with COPD or T2D compared with usual care. Amy Groenewegen shares the results.

Prescription rates of GLP-1RA and SGLT2i in patients with T2D and CVD

News - Oct. 9, 2023

EASD 2023 A real-life study investigated the prescription on glucose lowering agents in Swedish patients with T2D and CAD from 2010 to 2021.

Consistent benefit of SGLT2 inhibitors on CV outcomes across various patient populations

Literature - Sep. 21, 2023 - Usman MS, et al. - J Am Coll Cardiol. 2023

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

Special attention to glucose-lowering medication with proven CV benefit and/or safety in 2023 ESC diabetes guidelines

News - Sep. 12, 2023
New recommendations in the 2023 ESC guidelines for the management of CVD in patient with diabetes include focus on glucose-lowering medication with proven CV benefit and/or safety and the new SCORE2-Diabetes risk score.

ESC Congress 2023 New recommendations in the 2023 ESC guidelines for the management of CVD in patient with diabetes include focus on glucose-lowering medication with proven CV benefit and/or safety and the new SCORE2-Diabetes risk score.

Improvement of early diagnosis of CVD in primary care patients with COPD or T2D

News - Sep. 4, 2023

ESC Congress 2023 In the RED-CVD trial, it was shown that a proactive diagnostic intervention strategy improves early diagnosis of CVD in primary care patients with COPD and/or T2D.

Loneliness associated with higher CVD risk in DM

Literature - Aug. 7, 2023 - Wang X, et al. - Eur Heart J. 2023

A population-based cohort study showed that loneliness, but not social isolation, was associated with a higher CVD risk in patients with DM. Loneliness also ranked higher in relative strength for predicting CVD risk than lifestyle risk factors such as smoking and diet.

Elevated inflammation markers in diabetes: a cause or a consequence?

3' education - June 26, 2023 - Peter Libby, MD
**EAS Congress 2023** Some studies have demonstrated directionality from inflammation to diabetes. The next question is: can anti-inflammatory therapies halt the progression to diabetes?

EAS Congress 2023 Some studies have demonstrated directionality from inflammation to diabetes. The next question is: can anti-inflammatory therapies halt the progression to diabetes?

Increased prevalence of diabetes and obesity among young US adults

Literature - June 13, 2023 - Aggarwal R, et al. - JAMA. 2023

A serial cross-sectional analysis using data of the NHANES database investigated whether the prevalence of CV risk factors among young US adults changed from 2009 to March 2020.

Intermittent fasting plus early time-restricted eating in adults at risk of T2DM

Literature - June 12, 2023 - Tong Teong X, et al. - Nat Med. 2023

Does intermittent fasting plus early time-restricted eating provide greater improvements in glycemic control, weight management or CV markers compared to calorie restriction or standard care in adults at risk of T2DM? The authors investigated this in a three-arm parallel group sequential RCT.

Effect of optimal risk factor management on recurrent ASCVD risk

Literature - Apr. 4, 2023 - Van Trier TJ, et al. - Eur J Prev Cardiol. 2023

A pooled analysis of patients with established ASCVD showed a 10-year risk of recurrent ASCVD events of 20% and a lifetime risk of 54%. Theoretically, optimization of both lifestyle and medications could reduce both risks and add 7.3 event-free years.